Skip to main content

PDUFA Date

VERA: FDA Decision: trutakna

July 7, 2026 · trutakna · approval. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
July 7, 2026
Company
Vera Therapeutics, Inc. (VERA)
Drug
trutakna
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

PDUFA Dateapproval

FDA Decision: trutakna

Drug
trutakna
Indication
1 INDICATIONS AND USAGE TRUTAKNA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clin